The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates
Open accessAbstract
The increasing prevalence of poorly soluble drugs in development provides notable risk of new products demonstrating low and erratic bioavailability with consequences for safety and efficacy, particularly for drugs delivered by the oral route of administration. Although numerous strategies exist for enhancing the bioavailability of drugs with low aqueous solubility, the success of these approaches is not yet able to be guaranteed and is greatly dependent on the physical and chemical nature of the molecules being developed. Crystal engineering offers a number of routes to improved solubility and dissolution rate, which can be adopted through an in-depth knowledge of crystallisation processes and the molecular properties of active pharmaceutical ingredients. This article covers the concept and theory of crystal engineering and discusses the potential benefits, disadvantages and methods of preparation of co-crystals, metastable polymorphs, high-energy amorphous forms and ultrafine particles. Also considered within this review is the influence of crystallisation conditions on crystal habit and particle morphology with potential implications for dissolution and oral absorption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cambridge Structural Database: a quarter of a million crystal structures and rising
Allen, F. H. (2002) · Acta Crystallographica Section B Structural Science · doi:10.1107/s0108768102003890 · Cited by 9,898
The growth of crystals and the equilibrium structure of their surfaces
Burton, W. K., Cabrera, N., & Frank, F. C. (1951) · Philosophical Transactions of the Royal Society of London. Series A, Mathematical and Physical Sciences · doi:10.1098/rsta.1951.0006 · Cited by 5,339
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
Desiraju, G. R. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199523111 · Cited by 4,856
Encoding and decoding hydrogen-bond patterns of organic compounds
Etter, M. C. (1990) · Accounts of Chemical Research · doi:10.1021/ar00172a005 · Cited by 4,591
Lehn, J. (1988) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198800891 · Cited by 3,856
New software for searching the Cambridge Structural Database and visualizing crystal structures
Bruno, I. J., Cole, J. C., Edgington, P. R., Kessler, M., Macrae, C. F., McCabe, P., Pearson, J., & Taylor, R. (2002) · Acta Crystallographica Section B Structural Science · doi:10.1107/s0108768102003324 · Cited by 3,126
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Pharmaceutical Applications of Solid Dispersion Systems
Chiou, W. L., & Riegelman, S. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600600902 · Cited by 1,799
Robinson, B. H., & Kaler, E. W. (1999) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00026-1 · Cited by 1,766
Amorphous pharmaceutical solids: preparation, characterization and stabilization
Yu, L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00098-9 · Cited by 1,405
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Polymorphism in Molecular Crystals
Bernstein, J. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199236565.001.0001 · Cited by 1,346
Supercritical fluids as solvents for chemical and materials processing
Eckert, C. A., Knutson, B. L., & Debenedetti, P. G. (1996) · Nature · doi:10.1038/383313a0 · Cited by 923
Taylor, L. S., & Zografi, G. (1997) · Pharmaceutical Research · doi:10.1023/a:1012167410376 · Cited by 903
Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery
Rajewski, R. A., & Stella, V. J. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js960075u · Cited by 824
Hörter, D., & Dressman, J. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00130-7 · Cited by 819
Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API
McNamara, D. P., Childs, S. L., Giordano, J., Iarriccio, A., Cassidy, J., Shet, M. S., Mannion, R., O'Donnell, E., & Park, A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9032-3 · Cited by 690
Drug polymorphism and dosage form design: a practical perspective
Singhal, D. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.008 · Cited by 596
Lipid-based vehicles for the oral delivery of poorly water soluble drugs
Humberstone, A. J., & Charman, W. N. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00494-2 · Cited by 577
A third blind test of crystal structure prediction
Day, G. M., Motherwell, W. D. S., Ammon, H. L., Boerrigter, S. X. M., Della Valle, R. G., Venuti, E., Dzyabchenko, A., Dunitz, J. D., Schweizer, B., van Eijck, B. P., et al. (2005) · Acta Crystallographica Section B Structural Science · doi:10.1107/s0108768105016563 · Cited by 430
385. Topochemistry. Part III. The crystal chemistry of some trans-cinnamic acids
Schmidt, G. M. J. (1964) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9640002014 · Cited by 427
Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs
Hu, J., Johnston, K. P., & Williams, R. O. (2004) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120030422 · Cited by 387
Particle formation with supercritical fluids—a review
Tom, J. W., & Debenedetti, P. G. (1991) · Journal of Aerosol Science · doi:10.1016/0021-8502(91)90013-8 · Cited by 342
Supramolecular chemistry ? Scope and perspectives: Molecules ? Supermolecules ? Molecular devices
Lehn, J. (1988) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/bf00658981 · Cited by 330
Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate
Aguiar, A. J., Krc, J., Kinkel, A. W., & Samyn, J. C. (1967) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600560712 · Cited by 307
Forster, A., Hempenstall, J., & Rades, T. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775532 · Cited by 245
Türk, M., Hils, P., Helfgen, B., Schaber, K., Martin, H.-J., & Wahl, M. A. (2002) · The Journal of Supercritical Fluids · doi:10.1016/s0896-8446(01)00109-7 · Cited by 244
Micronization: A method of improving the bioavailability of poorly soluble drugs
Chaumeil, J. C. (1998) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.1998.20.3.485666 · Cited by 242
Strategies for particle design using supercritical fluid technologies
York, P. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00209-6 · Cited by 232
Self-citationWard, G. H., & Schultz, R. K. (1995) · Pharmaceutical Research · doi:10.1023/a:1016232230638 · Cited by 230
Perrut, M., Jung, J., & Leboeuf, F. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.09.007 · Cited by 215
Addadi, L., BERKOVITCH‐YELLIN, Z., Weissbuch, I., Lahav, M., & Leiserowitz, L. (1986) · Topics in stereochemistry · doi:10.1002/9780470147252.ch1 · Cited by 108
Improving the Dissolution and Bioavailability of Nifedipine Using Solid Dispersions and Solubilizers
Emara, L. H., Badr, M., & El-Bary, A. A. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120005625 · Cited by 106
The effect of the comminution technique on the surface energy of a powder
Buckton, G., Choularton, A., Beezer, A. E., & Chatham, S. M. (1988) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(88)90222-0 · Cited by 79
Tian, F., Sandler, N., Aaltonen, J., et al. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20756 · Cited by 70
Kushida, I., Ichikawa, M., & Asakawa, N. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10020 · Cited by 69
Thomson, G. P. (1948) · Proceedings of the Physical Society · doi:10.1088/0959-5309/61/5/302 · Cited by 54
In Vitro and In Vivo Evaluation of Glibenclamide in Solid Dispersion Systems
Tashtoush, B. M., Al‐Qashi, Z. S., & Najib, N. M. (2004) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120037491 · Cited by 51
Huang, C.-M., Leiserowitz, L., & Schmidt, G. M. J. (1973) · Journal of the Chemical Society Perkin Transactions 2 · doi:10.1039/p29730000503 · Cited by 43
Zhang, S. (2001) · Elsevier eBooks · doi:10.1016/b0-08-043152-6/01012-3 · Cited by 36
Cited by
Drug Solubility: Importance and Enhancement Techniques
Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012) · ISRN Pharmaceutics · doi:10.5402/2012/195727 · Cited by 2,004
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., Cho, J. M., Yun, G., & Lee, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.05.005 · Cited by 998
Metadata
- Authors
- Blagden, N., de Matas, M., Gavan, P. T., & York, P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 59
- Issue
- 7
- Pages
- 617-630
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1995008519
- Cited by
- 1,448
- References
- 40
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.